Ferumoxytol and Stroke: Assessing CNS Vascular Disease by Dósa, Edit
August 2013 
Brain  
Ferumoxytol and Stroke: Assessing CNS Vascular Disease 
Manninger SP, Muldoon LL, Nesbit G, et al. An Exploratory Study of Ferumoxtran-10 
Nanoparticles as a Blood-Brain Barrier Imaging Agent Targeting Phagocytic Cells in CNS 
Inflammatory Lesions. AJNR Am J Neuroradiol 2005;26:2290-300. 
 
Edit Dósa 
Ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles may have benefit over 
gadolinium-based contrast agents (GBCA) for neuroimaging. Using ferumoxtran-10 in 
patients with brain tumors, we demonstrated that delayed (24 hours) changes in MR signal 
intensity in the brain are not due to tumor cells but rather the intracellular endocytosis of iron 
oxide particles in reactive cells that are mainly at the tumor margin and necrotic regions. This 
finding led us to investigate the utility of MRI with ferumoxtran-10 in other neurologic 
conditions that are associated with reactive cells, including demyelinating, cerebrovascular, 
and hematopoietic malignant CNS lesions, with the goal of identifying which lesion type(s) 
should be investigated in more focused trials. We observed that MRI with ferumoxtran-10 
showed different size and location of lesions in primary CNS lymphoma and in other CNS 
inflammatory disorders than imaging with GBCA. In some cases, ferumoxtran-10—in other 
cases, GBCA—showed more intense or different volumes of enhancement. Ferumoxtran-10 
did not enhance as well in multiple sclerosis as it did in other inflammatory lesions or tumors, 
which may be indicative of different blood-brain barrier defects or phagocytic cell specificity 
in these different lesions. 
Subsequent studies used the FDA-approved USPIO ferumoxytol in patients with intracerebral 
neoplasms (largely glioblastoma).
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 We have carefully evaluated MRI sequences and timing 
in the same patients scanned on 3 consecutive days (day 1: GBCA; day 2: ferumoxytol; day 3: 
follow-up for ferumoxytol with no additional contrast) at various magnetic field strengths up 
to 7T. We have found that ferumoxytol is safe and effective for imaging CNS neoplasms and 
inflammatory lesions. Direct comparison of GBCA and ferumoxytol for tumor imaging 
showed greater signal intensity changes on T1WI with GBCA compared to delayed 
ferumoxytol (P <.0001), but there was no significant difference in lesion enhancement 
volumes, particularly in untreated glioblastoma. Ferumoxytol-induced signal changes were 
noted in areas with no gadoteridol enhancement in 6 patients.
1,2
 T2WI obtained 24–72 hours 
after ferumoxytol showed hypointensity (signal dropout) associated with nanoparticle 
accumulation in 26 of 49 patients
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 and 16 of 26 patients
2
 in 2 reports. Delayed signal changes 




My main interest involves the visualization of CNS vascular malformations with USPIO. 
Vascular malformations may have variable degrees of inflammation that may be relevant 
clinically. Arteriovenous malformations may demonstrate increased expression of 
inflammatory cytokines, and macrophages are frequently present within resected surgical 
specimens of AVM (including up to 30% of unruptured AVM) and cavernous malformation. 
Postferumoxytol susceptibility-weighted images revealed capillary telangiectasias and 
cavernomas that were completely unnoticeable on the no-contrast and post-GBCA images.
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We also demonstrated additional tributary veins in all patients with developmental venous 
anomalies (Figure 1). Hasan et al
5
 showed that ferumoxytol given to patients with AVM could 
be visualized as T2 hypointense signal within the AVM nidus and vascular walls. Histology 
confirmed macrophage staining within vessel walls in one of these cases. Because 
ferumoxytol is taken up by phagocytic leukocytes and, in particular, by macrophages, it could 
prove useful for monitoring inflammation within “at risk” AVMs or cavernomas at higher risk 
of rupture. The superiority of ferumoxytol compared to GBCA for detection of intracranial 
vascular malformations may be on the basis of superior intravascular contrast with T2*-
weighted sequences, in addition to inflammatory cellular uptake. Our future goal is to 
investigate the use of ferumoxytol as a macrophage-imaging agent in the visualization of 
inflammatory cells within and around AVMs. 
 
Figure 1. Developmental venous anomaly. Axial susceptibility-weighted images obtained 
before (A) and 25 minutes after ferumoxytol administration (B). Although the left cerebellar 
lesion is visible on both the pre- and post-ferumoxytol susceptibility-weighted images, the 
ferumoxytol scan demonstrates additional tributary veins (rectangle) compared with the 
precontrast sequence. Published in Dósa et al, Stroke 2011.4 
With more than 10 years of experience behind us, we believe that USPIO-enhanced MRI 
offers a number of potential advantages over conventional GBCA-enhanced MRI in the 
diagnostic workup of CNS lymphoma and inflammatory intracranial neoplastic mimics. First, 
USPIO-enhanced MRI may give different or additional areas of enhancement that may offer 
improved surgical targeting opportunities. This may be particularly true for T2-weighted 
enhanced scans with USPIO, which may offer an alternative sampling site for biopsy to 
conventional postcontrast T1WI with gadolinium. Second, ferumoxytol, in contrast to 
ferumoxtran-10, can be administered via rapid IV bolus injection and can be used for dynamic 
imaging in addition to anatomic imaging. Ferumoxytol-based dynamic susceptibility-
weighted contrast-enhanced  perfusion MRI may offer discrimination of inflammatory 
diseases, such as demyelination, from neoplastic disorders. Third, USPIO can be used safely 
in patients with renal failure who cannot receive gadolinium.
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However, every coin has two sides; the USPIO-enhanced MRI has limitations as well. These 
limitations include the following: 1) requirement for at least 2 consecutive days of imaging to 
obtain anatomic “enhanced” scans similar to GBCA-enhanced MRI, 2) ferumoxytol-based 
DSC perfusion MRI, similar to GBCA-based DSC perfusion MRI, alone remains unable to 
discriminate between malignant lymphoid and glial neoplasms, and 3) the potential for 
USPIO enhancement rarely to persist up to several months after injection may result in 
confusion for hemorrhage. 
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